| . | PI Group (n = 18) . | Intensive MMT Group (n = 30) . | Total (N = 48) . |
|---|---|---|---|
| Sex | |||
| Male | 7 (39) | 22 (73) | 29 (60) |
| Female | 11 (61) | 8 (27) | 19 (40) |
| Age at diagnosis, median (range), y | 67.5 (50.0–88.0) | 60.0 (37.0–84.0) | 62.0 (37.0–88.0) |
| Histology | |||
| ATC only | 13 (72) | 16 (53) | 29 (60) |
| Associated with DTC | 5 (28) | 14 (47) | 19 (40) |
| Type of ATC | |||
| Nondescript | 11 (61) | 22 (73) | 33 (69) |
| Sarcomatoid | 5 (28) | 7 (23) | 12 (25) |
| Others | 2 (11) | 1 (3) | 3 (6) |
| AJCC stagea | |||
| IVa | 0 (0.0) | 2 (7) | 2 (4) |
| IVb | 5 (29) | 22 (73) | 27 (57) |
| IVc | 12 (71) | 6 (20) | 18 (38) |
| Clinical disease extent, classa | |||
| 1 | 0 (0) | 2 (7) | 2 (4) |
| 2 | 5 (29) | 17 (57) | 22 (47) |
| 3 | 1 (6) | 6 (20) | 7 (15) |
| 4 | 10 (59) | 5 (17) | 15 (32) |
| 5 | 1 (6) | 0 (0) | 1 (2) |
| . | PI Group (n = 18) . | Intensive MMT Group (n = 30) . | Total (N = 48) . |
|---|---|---|---|
| Sex | |||
| Male | 7 (39) | 22 (73) | 29 (60) |
| Female | 11 (61) | 8 (27) | 19 (40) |
| Age at diagnosis, median (range), y | 67.5 (50.0–88.0) | 60.0 (37.0–84.0) | 62.0 (37.0–88.0) |
| Histology | |||
| ATC only | 13 (72) | 16 (53) | 29 (60) |
| Associated with DTC | 5 (28) | 14 (47) | 19 (40) |
| Type of ATC | |||
| Nondescript | 11 (61) | 22 (73) | 33 (69) |
| Sarcomatoid | 5 (28) | 7 (23) | 12 (25) |
| Others | 2 (11) | 1 (3) | 3 (6) |
| AJCC stagea | |||
| IVa | 0 (0.0) | 2 (7) | 2 (4) |
| IVb | 5 (29) | 22 (73) | 27 (57) |
| IVc | 12 (71) | 6 (20) | 18 (38) |
| Clinical disease extent, classa | |||
| 1 | 0 (0) | 2 (7) | 2 (4) |
| 2 | 5 (29) | 17 (57) | 22 (47) |
| 3 | 1 (6) | 6 (20) | 7 (15) |
| 4 | 10 (59) | 5 (17) | 15 (32) |
| 5 | 1 (6) | 0 (0) | 1 (2) |
Data given as no. (%) unless otherwise indicated.
Abbreviation: DTC, differentiated thyroid cancer.
Missing data for one patient.
| . | PI Group (n = 18) . | Intensive MMT Group (n = 30) . | Total (N = 48) . |
|---|---|---|---|
| Sex | |||
| Male | 7 (39) | 22 (73) | 29 (60) |
| Female | 11 (61) | 8 (27) | 19 (40) |
| Age at diagnosis, median (range), y | 67.5 (50.0–88.0) | 60.0 (37.0–84.0) | 62.0 (37.0–88.0) |
| Histology | |||
| ATC only | 13 (72) | 16 (53) | 29 (60) |
| Associated with DTC | 5 (28) | 14 (47) | 19 (40) |
| Type of ATC | |||
| Nondescript | 11 (61) | 22 (73) | 33 (69) |
| Sarcomatoid | 5 (28) | 7 (23) | 12 (25) |
| Others | 2 (11) | 1 (3) | 3 (6) |
| AJCC stagea | |||
| IVa | 0 (0.0) | 2 (7) | 2 (4) |
| IVb | 5 (29) | 22 (73) | 27 (57) |
| IVc | 12 (71) | 6 (20) | 18 (38) |
| Clinical disease extent, classa | |||
| 1 | 0 (0) | 2 (7) | 2 (4) |
| 2 | 5 (29) | 17 (57) | 22 (47) |
| 3 | 1 (6) | 6 (20) | 7 (15) |
| 4 | 10 (59) | 5 (17) | 15 (32) |
| 5 | 1 (6) | 0 (0) | 1 (2) |
| . | PI Group (n = 18) . | Intensive MMT Group (n = 30) . | Total (N = 48) . |
|---|---|---|---|
| Sex | |||
| Male | 7 (39) | 22 (73) | 29 (60) |
| Female | 11 (61) | 8 (27) | 19 (40) |
| Age at diagnosis, median (range), y | 67.5 (50.0–88.0) | 60.0 (37.0–84.0) | 62.0 (37.0–88.0) |
| Histology | |||
| ATC only | 13 (72) | 16 (53) | 29 (60) |
| Associated with DTC | 5 (28) | 14 (47) | 19 (40) |
| Type of ATC | |||
| Nondescript | 11 (61) | 22 (73) | 33 (69) |
| Sarcomatoid | 5 (28) | 7 (23) | 12 (25) |
| Others | 2 (11) | 1 (3) | 3 (6) |
| AJCC stagea | |||
| IVa | 0 (0.0) | 2 (7) | 2 (4) |
| IVb | 5 (29) | 22 (73) | 27 (57) |
| IVc | 12 (71) | 6 (20) | 18 (38) |
| Clinical disease extent, classa | |||
| 1 | 0 (0) | 2 (7) | 2 (4) |
| 2 | 5 (29) | 17 (57) | 22 (47) |
| 3 | 1 (6) | 6 (20) | 7 (15) |
| 4 | 10 (59) | 5 (17) | 15 (32) |
| 5 | 1 (6) | 0 (0) | 1 (2) |
Data given as no. (%) unless otherwise indicated.
Abbreviation: DTC, differentiated thyroid cancer.
Missing data for one patient.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
